Multiple Sclerosis

Ocrevus infusions were effective in halting disease activity in Black and Hispanic individuals with relapsing forms of multiple sclerosis after 1 year, according to a study presented at ECTRIMS 2023.

As a neuro clinical specialist in physical therapy, I treat many people with multiple sclerosis.

PHILADELPHIA — A genetic risk test for patients with multiple sclerosis can identify drugs that may lead to development of progressive multifocal leukoencephalopathy, per data presented at the American Neurological Association annual meeting.

Tracking data from white matter lesions on structural imaging via a circuit-based approach may assist in prognosis of memory and other higher order deficits for those with multiple sclerosis, per research published in Journal of Neurology.

The FDA has approved Tyruko, the first biosimilar to Tysabri injection, for the treatment of adults with relapsing forms of multiple sclerosis.

For individuals with relapsing-remitting multiple sclerosis, fatigue levels were associated with disability rate, physical conditioning and activity level, according to research from Multiple Sclerosis and Related Disorders.

Longer-term treatment with ofatumumab led to lessening of disability progression and slowing of brain volume loss, according to Jeffrey A. Cohen, MD, in this Healio video.

For those with relapsing multiple sclerosis, continuous treatment with Kesimpta demonstrated sustained efficacy for annual relapse rates as well as significant suppression of MRI lesion activity for up to 5 years, according to research.

A Bay Area-based precision care company has announced $30 million in funding to continue providing care for those with multiple sclerosis and other neurodegenerative diseases.